Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Timeline
  • Published:

Helicobacter pylori: perspectives and time trends

Nature Reviews Gastroenterology & Hepatology volume 11, pages 628–638 (2014)Cite this article

Subjects

Abstract

The discovery of Helicobacter pylori three decades ago is a modern medical success story. It markedly changed our understanding of the pathophysiology of gastroduodenal diseases and led to an improvement in the treatment of diseases related to H. pylori infection. Many of these diseases (such as ulcer disease and mucosal associated lymphoid tissue lymphoma) have become curable, and others (gastric cancer) might be preventable with the application of H. pylori eradication therapy. Since its discovery, H. pylori has also been identified as a trigger for some extragastric diseases. Promising results in this exciting field might have a clinical effect in the near future. This Timeline gives an overview of the success of clinical research on H. pylori to date and highlights some future trends in this area.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Ito, S. in Handbook of Physiology 705–741 (American Physiological Society, 1967).

    Google Scholar 

  2. Krienitz, W. Ueber das Auftreten von Spirochäten verschiedener Formen im Mageninhalt bei Carcinoma ventriculi. 32, 872 (1906).

  3. Fung, W. P., Papadimitriou, J. M. & Matz, L. R. Endoscopic, histological and ultrastructural correlations in chronic gastritis. Am. J. Gastroenterol. 71, 269–279 (1979).

    CAS  PubMed  Google Scholar 

  4. Pincock, S. Nobel Prize winners Robin Warren and Barry Marshall. Lancet 366, 1429 (2005).

    Article  PubMed  Google Scholar 

  5. Marshall, B. J. & Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311–1315 (1984).

    Article  CAS  PubMed  Google Scholar 

  6. Marshall, B. J., Armstrong, J. A., McGechie, D. B. & Galncy, R. J. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med. J. Aust. 142, 436–439 (1985).

    Article  CAS  PubMed  Google Scholar 

  7. Gustavsson, S. & Malfertheiner, P. (eds) Campylobacter pylori in gastroduodenal diseases: current views—future directions. Proceedings of an international workshop. Copenhagen, 15 and 16 October 1987. Scand. J Gastroenterol. Suppl. 142, 1–116 (1988).

    Google Scholar 

  8. Goodwin, C. S. & Armstrong, J. A. Microbiological aspects of Helicobacter pylori (Campylobacter pylori). Eur. J. Clin. Microbiol. Infect. Dis. 9, 1–13 (1990).

    Article  CAS  PubMed  Google Scholar 

  9. Cussac, V., Ferrero, R. L. & Labigne, A. Expression of Helicobacter pylori urease genes in Escherichia coli grown under nitrogen-limiting conditions. J. Bacteriol. 174, 2466–2473 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Eaton, K. A., Brooks, C. L., Morgan, D. R. & Krawkowka, S. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect. Immun. 59, 2470–2475 (1991).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Labigne, A., Cussac, V. & Courcoux, P. Shuttle cloning and nucleotide sequences of Helicobacter pylori genes responsible for urease activity. J. Bacteriol. 173, 1920–1931 (1991).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Perez-Perez, G. I., Olivares, A. Z., Cover, T. L. & Blaser, M. J. Characteristics of Helicobacter pylori variants selected for urease deficiency. Infect. Immun. 60, 3658–3663 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Leying, H., Suerbaum, S., Geis, G. & Haas, R. Cloning and genetic characterization of a Helicobacter pylori flagellin gene. Mol. Microbiol. 6, 2863–2874 (1992).

    Article  CAS  PubMed  Google Scholar 

  14. Leunk, R. D., Johnson, P. T., David, B. C., Kraft, W. G. & Morgan, D. R. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J. Med. Microbiol. 26, 93–99 (1988).

    Article  CAS  PubMed  Google Scholar 

  15. Cover, T. L. & Blaser, M. J. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J. Biol. Chem. 267, 10570–10575 (1992).

    Article  CAS  PubMed  Google Scholar 

  16. Telford, J. L. et al. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J. Exp. Med. 179, 1653–1658 (1994).

    Article  CAS  PubMed  Google Scholar 

  17. Schmitt, W. & Haas, R. Genetic analysis of the Helicobacter pylori vacuolating cytotoxin: structural similarities with the IgA protease type of exported protein. Mol. Microbiol. 12, 307–319 (1994).

    Article  CAS  PubMed  Google Scholar 

  18. Phadnis, S. H., Ilver, D., Janzon, L., Normark, S. & Westblom, T. U. Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori. Infect. Immun. 62, 1557–1565 (1994).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cover, T. L., Tummuru, M. K., Cao, P., Thompson, S. A. & Blaser, M. J. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J. Biol. Chem. 269, 10566–10573 (1994).

    Article  CAS  PubMed  Google Scholar 

  20. Atherton, J. C. et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J. Biol. Chem. 270, 17771–17777 (1995).

    Article  CAS  PubMed  Google Scholar 

  21. Rhead, J. L. et al. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology 133, 926–936 (2007).

    Article  CAS  PubMed  Google Scholar 

  22. Apel, I., Jacobs, E., Kist, M. & Bredt, W. Antibody response of patients against a 120 kDa surface protein of Campylobacter pylori. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 268, 271–276 (1988).

    CAS  PubMed  Google Scholar 

  23. Tummuru, M. K., Cover, T. L. & Blaser, M. J. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production. Infect. Immun. 61, 1799–1809 (1993).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Covacci, A. et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc. Natl Acad. Sci. USA 90, 5791–5795 (1993).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tummuru, M. K., Sharma, S. A. & Blaser, M. J. Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol. Microbiol. 18, 867–876 (1995).

    Article  CAS  PubMed  Google Scholar 

  26. Censini, S. et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl Acad. Sci. USA 93, 14648–14653 (1996).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Odenbreit, S. et al. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 287, 1497–1500 (2000).

    Article  CAS  PubMed  Google Scholar 

  28. Ohnishi. N. et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc. Natl Acad. Sci. USA 105, 1003–1008 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Evans, D. J. Jr et al. Characterization of a Helicobacter pylori neutrophil-activating protein. Infect. Immun. 63, 2213–2220 (1995).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yamaoka, Y., Kwon, D. H. & Graham, D. Y. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc. Natl Acad. Sci. USA 97, 7533–7538 (2000).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ilver, D. et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 279, 373–377 (1998).

    Article  CAS  PubMed  Google Scholar 

  32. Yu, J. et al. Relationship between Helicobacter pylori babA2 status with gastric epithelial cell turnover and premalignant gastric lesions. Gut 51, 480–484 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Prinz, C. et al. Key importance of the Helicobacter pylori adherence factor blood group antigen binding adhesin during chronic gastric inflammation. Cancer Res. 61, 1903–1909 (2001).

    CAS  PubMed  Google Scholar 

  34. Gerhard, M. et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc. Natl Acad. Sci. USA 96, 12778–12783 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Peek, R. M. Jr et al. Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome. Proc. Assoc. Am. Physicians 110, 531–544 (1998).

    CAS  PubMed  Google Scholar 

  36. Lu, H., Hsu, P. I., Graham, D. Y. & Yamaoka, Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 128, 833–848 (2005).

    Article  CAS  PubMed  Google Scholar 

  37. Tomb, J. F. et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388, 539–547 (1997).

    Article  CAS  PubMed  Google Scholar 

  38. Wotherspoon, A. C., Ortiz-Hidalgo, C., Falzon, M. R. & Isaacson, P. G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338, 1175–1176 (1991).

    Article  CAS  PubMed  Google Scholar 

  39. Uemura, N. et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784–789 (2001).

    Article  CAS  PubMed  Google Scholar 

  40. Nobel Assembly. Press Release: the Nobel Prize in Physiology or Medicine 2005—Barry J. Marshall and J. Robin Warren. NobelPrize.org [online], (2005).

  41. Coghlan, J. G. et al. Campylobacter pylori and recurrence of duodenal ulcers—a 12-month follow-up study. Lancet 2, 1109–1111 (1987).

    Article  CAS  PubMed  Google Scholar 

  42. Rauws, E. A. & Tytgat, G. N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335, 1233–1235 (1990).

    Article  CAS  PubMed  Google Scholar 

  43. Hosking, S. W. et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 343, 508–510 (1994).

    Article  CAS  PubMed  Google Scholar 

  44. McColl, K. E., Gillen, D. & El-Omar, E. The role of gastrin in ulcer pathogenesis. Baillieres Best. Pract. Res. Clin. Gastroenterol. 14, 13–26 (2000).

    Article  CAS  PubMed  Google Scholar 

  45. Olbe, L., Hamlet, A., Dalenback, J. & Fandriks, L. A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 110, 1386–1394 (1996).

    Article  CAS  PubMed  Google Scholar 

  46. Malfertheiner, P., Chan, F. K. & McColl, K. E. Peptic ulcer disease. Lancet 374, 1449–1461 (2009).

    Article  CAS  PubMed  Google Scholar 

  47. Yamaoka, Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat. Rev. Gastroenterol. Hepatol. 7, 629–641 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Charpignon, C. et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment. Pharmacol. Ther. 38, 946–954 (2013).

    Article  CAS  PubMed  Google Scholar 

  49. Selgrad, M., Bornschein, J. & Malfertheiner, P. Guidelines for treatment of Helicobacter pylori in the East and West. Expert. Rev. Anti. Infect. Ther. 9, 581–588 (2011).

    Article  PubMed  Google Scholar 

  50. Stolte, M. & Eidt, S. Lymphoid follicles in antral mucosa: immune response to Campylobacter pylori? J. Clin. Pathol. 42, 1269–1271 (1989).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wyatt, J. I. & Rathbone, B. J. Immune response of the gastric mucosa to Campylobacter pylori. Scand. J. Gastroenterol. Suppl. 142, 44–49 (1988).

    Article  CAS  PubMed  Google Scholar 

  52. Wotherspoon, A. C. et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342, 575–577 (1993).

    Article  CAS  PubMed  Google Scholar 

  53. Zullo, A. et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am. J. Gastroenterol. 104, 1932–1937 (2009).

    Article  CAS  PubMed  Google Scholar 

  54. Fischbach, W. et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 56, 1685–1687 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Boot, H., de Jong, D., van Heerde, P. & Taal, B. Role of Helicobacter pylori eradication in high-grade MALT lymphoma. Lancet 346, 448–449 (1995).

    Article  CAS  PubMed  Google Scholar 

  56. Bayerdorffer, E. et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 345, 1591–1594 (1995).

    Article  CAS  PubMed  Google Scholar 

  57. Ruskone-Fourmestraux, A. et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 60, 747–758 (2011).

    Article  CAS  PubMed  Google Scholar 

  58. Ruskone-Fourmestraux, A. et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 48, 297–303 (2001).

    Article  CAS  PubMed  Google Scholar 

  59. Morgner, A. et al. Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type. World J. Gastroenterol. 7, 248–253 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Horstmann, M., Erttmann, R. & Winkler, K. Relapse of MALT lymphoma associated with Helicobacter pylori after antibiotic treatment. Lancet 343, 1098–1099 (1994).

    Article  CAS  PubMed  Google Scholar 

  61. Hussell, T., Isaacson, P. G., Crabtree, J. E. & Spencer, J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 342, 571–574 (1993).

    Article  CAS  PubMed  Google Scholar 

  62. Sagaert, X. et al. Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat. Rev. Gastroenterol. Hepatol. 7, 336–346 (2010).

    Article  CAS  PubMed  Google Scholar 

  63. Horsman, D., Gascoyne, R., Klasa, R. & Coupland, R. t(11;18)(q21;q21.1): a recurring translocation in lymphomas of mucosa-associated lymphoid tissue (MALT)? Genes Chromosomes Cancer 4, 183–187 (1992).

    Article  CAS  PubMed  Google Scholar 

  64. Ott, G. et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res. 57, 3944–3948 (1997).

    CAS  PubMed  Google Scholar 

  65. Auer, I. A. et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann. Oncol. 8, 979–985 (1997).

    Article  CAS  PubMed  Google Scholar 

  66. Dierlamm, J. et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601–3609 (1999).

    Article  CAS  PubMed  Google Scholar 

  67. Liu, H. et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357, 39–40 (2001).

    Article  CAS  PubMed  Google Scholar 

  68. Liu, H. et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to, H. pylori eradication. Gastroenterology 122, 1286–1294 (2002).

    Article  CAS  PubMed  Google Scholar 

  69. de Jong, D. et al. Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA. Am. J. Clin. Pathol. 106, 670–675 (1996).

    Article  CAS  PubMed  Google Scholar 

  70. Delchier, J. C. et al. Helicobacter pylori and gastric lymphoma: high seroprevalence of CagA in diffuse large B-cell lymphoma but not in low-grade lymphoma of mucosa-associated lymphoid tissue type. Am. J. Gastroenterol. 96, 2324–2328 (2001).

    Article  CAS  PubMed  Google Scholar 

  71. Ye, H. et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 102, 1012–1018 (2003).

    Article  CAS  PubMed  Google Scholar 

  72. Thiberge, J. M. et al. From array-based hybridization of Helicobacter pylori isolates to the complete genome sequence of an isolate associated with MALT lymphoma. BMC Genomics 11, 368 (2010).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Lehours, P., Zheng, Z., Skoglund, A., Megraud, F. & Engstrand, L. Is there a link between the lipopolysaccharide of Helicobacter pylori gastric MALT lymphoma associated strains and lymphoma pathogenesis? PLoS ONE 4, e7297 (2009).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Parsonnet, J. et al. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J Med. 325, 1127–1131 (1991).

    Article  CAS  PubMed  Google Scholar 

  75. [No authors listed] Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 61, 1–241 (1994).

  76. Watanabe, T., Tada, M., Nagai, H., Sasaki, S. & Nakao, M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 115, 642–648 (1998).

    Article  CAS  PubMed  Google Scholar 

  77. Kato, S. et al. High salt diets dose-dependently promote gastric chemical carcinogenesis in Helicobacter pylori-infected Mongolian gerbils associated with a shift in mucin production from glandular to surface mucous cells. Int. J. Cancer 119, 1558–1566 (2006).

    Article  CAS  PubMed  Google Scholar 

  78. Malfertheiner. P. et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am. J. Gastroenterol. 100, 2100–2115 (2005).

    Article  PubMed  Google Scholar 

  79. Wroblewski, L. E., Peek, R. M. Jr & Wilson, K. T. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin. Microbiol. Rev. 23, 713–739 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Liu, H. et al. Diet synergistically affects Helicobacter pylori-induced gastric carcinogenesis in nonhuman primates. Gastroenterology 137, 1367–1379 (2009).

    Article  CAS  PubMed  Google Scholar 

  81. Bornschein, J. et al. Molecular diagnostics in gastric cancer. Front Biosci. (Landmark Ed.) 19, 312–338 (2014).

    Article  CAS  Google Scholar 

  82. Yamaoka, Y., Reddy, R. & Graham, D. Y. Helicobacter pylori virulence factor genotypes in children in the United States: clues about genotype and outcome relationships. J. Clin. Microbiol. 48, 2550–2551 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Blaser, M. J. et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 55, 2111–2115 (1995).

    CAS  PubMed  Google Scholar 

  84. Enroth, H., Kraaz, W., Engstrand, L., Nyren, O. & Rohan, T. Helicobacter pylori strain types and risk of gastric cancer: a case-control study. Cancer Epidemiol. Biomarkers Prev. 9, 981–985 (2000).

    CAS  PubMed  Google Scholar 

  85. Hatakeyama, M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat. Rev. Cancer 4, 688–694 (2004).

    Article  CAS  PubMed  Google Scholar 

  86. El-Omar, E. M. et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398–402 (2000).

    Article  CAS  PubMed  Google Scholar 

  87. El-Omar, E. M. et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124, 1193–1201 (2003).

    Article  CAS  PubMed  Google Scholar 

  88. Hou, L. et al. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis 28, 118–123 (2007).

    Article  CAS  PubMed  Google Scholar 

  89. Crusius, J. B. et al. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann. Oncol. 19, 1894–1902 (2008).

    Article  CAS  PubMed  Google Scholar 

  90. Saeki, N., Ono, H., Sakamoto, H. & Yoshida, T. Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study. Cancer Sci. 104, 1–8 (2013).

    Article  CAS  PubMed  Google Scholar 

  91. Figueiredo, C. et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J. Natl Cancer Inst. 94, 1680–1687 (2002).

    Article  CAS  PubMed  Google Scholar 

  92. Gonzalez, C. A., Sala, N. & Rokkas, T. Gastric cancer: epidemiologic aspects. Helicobacter 18 (Suppl. 1), 34–38 (2013).

    Article  PubMed  Google Scholar 

  93. Figueiredo, C., Garcia-Gonzalez, M. A. & Machado, J. C. Molecular pathogenesis of gastric cancer. Helicobacter 18 (Suppl. 1), 28–33 (2013).

    Article  PubMed  Google Scholar 

  94. Wang, S. K. et al. CagA+ H pylori infection is associated with polarization of T helper cell immune responses in gastric carcinogenesis. World J. Gastroenterol. 13, 2923–2931 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Kandulski, A., Malfertheiner, P. & Wex, T. Role of regulatory T-cells in, H. pylori-induced gastritis and gastric cancer. Anticancer Res. 30, 1093–1103 (2010).

    CAS  PubMed  Google Scholar 

  96. Fuccio, L. et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med. 151, 121–128 (2009).

    Article  PubMed  Google Scholar 

  97. Wong, B. C. et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291, 187–194 (2004).

    Article  CAS  PubMed  Google Scholar 

  98. Fukase, K. et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372, 392–397 (2008).

    Article  PubMed  Google Scholar 

  99. Fock, K. M. et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 24, 1587–1600 (2009).

    Article  PubMed  Google Scholar 

  100. Malfertheiner, P. et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 61, 646–664 (2012).

    Article  CAS  PubMed  Google Scholar 

  101. Ma, J. L. et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J. Natl Cancer Inst. 104, 488–492 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Lee, Y. C. et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 62, 676–682 (2013).

    Article  PubMed  Google Scholar 

  103. Selgrad, M., Kandulski, A. & Malfertheiner, P. Helicobacter pylori: diagnosis and treatment. Curr. Opin. Gastroenterol. 25, 549–556 (2009).

    Article  PubMed  Google Scholar 

  104. Mendall, M. A. et al. Relation of Helicobacter pylori infection and coronary heart disease. Br. Heart J. 71, 437–439 (1994).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Gasbarrini, A. et al. Helicobacter pylori infection and vascular diseases. Ital. J. Gastroenterol. Hepatol. 30 (Suppl. 3), S307–S309 (1998).

    CAS  PubMed  Google Scholar 

  106. Gillum, G. F. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. J. Natl Med. Assoc. 96, 1470–1476 (2004).

    PubMed  PubMed Central  Google Scholar 

  107. Pasceri, V. et al. Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. Am. Heart J. 151, 1215–1222 (2006).

    Article  CAS  PubMed  Google Scholar 

  108. Franceschi, F. et al. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis 202, 535–542 (2009).

    Article  CAS  PubMed  Google Scholar 

  109. Birnie, D. H. et al. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur. Heart J. 19, 387–394 (1998).

    Article  CAS  PubMed  Google Scholar 

  110. Venerito, M., Selgrad, M. & Malfertheiner, P. Helicobacter pylori: gastric cancer and extragastric malignancies—clinical aspects. Helicobacter 18 (Suppl. 1), 39–43 (2013).

    Article  PubMed  Google Scholar 

  111. Roubaud-Baudron, C., Krolak-Salmon, P., Quadrio, I., Megradu, F. & Salles, N. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiol. Aging 33, 1009.e11–9 (2012).

    Article  CAS  Google Scholar 

  112. Franceschi, F. & Gasbarrini, A. Helicobacter pylori and extragastric diseases. Best. Pract. Res. Clin. Gastroenterol. 21, 325–334 (2007).

    Article  CAS  PubMed  Google Scholar 

  113. Tebbe, B. et al. Helicobacter pylori infection and chronic urticaria. J. Am. Acad. Dermatol. 34, 685–686 (1996).

    Article  CAS  PubMed  Google Scholar 

  114. Zentilin, P. et al. Eradication of Helicobacter pylori may reduce disease severity in rheumatoid arthritis. Aliment. Pharmacol. Ther. 16, 1291–1299 (2002).

    Article  CAS  PubMed  Google Scholar 

  115. Sonnenberg, A. & Genta, R. M. Helicobacter pylori is a risk factor for colonic neoplasms. Am. J. Gastroenterol. 108, 208–215 (2013).

    Article  PubMed  Google Scholar 

  116. Labenz, J. et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112, 1442–1447 (1997).

    Article  CAS  PubMed  Google Scholar 

  117. Richter, J. E. Effect of Helicobacter pylori eradication on the treatment of gastro-oesophageal reflux disease. Gut 53, 310–311 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Malfertheiner, P. Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease. Gut 53, 312–313 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Zullo, A., Hassan, C., Repici, A. & Bruzzese, V. Helicobacter pylori eradication and reflux disease onset: did gastric acid get “crazy”? World J. Gastroenterol. 19, 786–789 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  120. Wang, C., Yuan, Y. & Hunt, R. H. Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis,” Am. J. Gastroenterol. 104, 492–500 (2009).

    Article  PubMed  Google Scholar 

  121. Saad, A. M., Choudhary, A. & Bechtold, M. L. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand. J. Gastroenterol. 47, 129–135 (2012).

    Article  PubMed  Google Scholar 

  122. Chen, Y. & Blaser, M. J. Helicobacter pylori colonization is inversely associated with childhood asthma. J. Infect. Dis. 198, 553–560 (2008).

    Article  PubMed  Google Scholar 

  123. Arnold, I. C. et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J. Clin. Invest. 121, 3088–3093 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Oertli, M. et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J. Clin. Invest. 122, 1082–1096 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Cover, T. L. & Blaser, M. J. Helicobacter pylori in health and disease. Gastroenterology 136, 1863–1873 (2009).

    Article  CAS  PubMed  Google Scholar 

  126. Rauws, E. A., Langenberg, W., Houthoff, H. J., Zanen, H. C. & Tytgat, G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 94, 33–40 (1988).

    Article  CAS  PubMed  Google Scholar 

  127. McNulty, C. A. et al. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br. Med. J. (Clin. Res. Ed.) 293, 645–649 (1986).

    Article  CAS  Google Scholar 

  128. Oderda, G., Dell-Olio, D., Morra, I. & Ansaldi, N. Campylobacter pylori gastritis: long term results of treatment with amoxycillin. Arch. Dis. Child. 64, 326–329 (1989).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Malfertheiner, P. et al. Bismuth subsalicylate treatment in chronic Campylobacter pylori-associated erosive gastritis [German]. Dtsch Med. Wochenschr. 113, 923–929 (1988).

    Article  CAS  PubMed  Google Scholar 

  130. Glupczynski, Y. et al. Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am. J. Gastroenterol. 83, 365–372 (1988).

    CAS  PubMed  Google Scholar 

  131. Marshall, B. J., Armstrong, J. A., Francis, G. J., Nokes, N. T. & Wee, S. H. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 37 (Suppl. 2), 16–30 (1987).

    Article  PubMed  Google Scholar 

  132. Wagner, S., Freise, J., Bar, W., Fritsch, S. & Schmidt, F. W. Epidemiology and therapy of Campylobacter pylori infection [German]. 114, 407–413 (1989).

  133. Graham, D. Y., Lew, G. M., Evans, D. G., Evans, D. J. Jr & Klein, P. D. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann. Intern. Med. 115, 266–269 (1991).

    Article  CAS  PubMed  Google Scholar 

  134. Bell, G. D. et al. Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment. Pharmacol. Ther. 6, 427–435 (1992).

    Article  CAS  PubMed  Google Scholar 

  135. Borody, T. J. et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 37, 477–481 (1995).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Hosking, S. W. et al. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ 305, 502–504 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Rauws, E. A., Langenberg, W., Bosma, A., Dankert, J. & Tytgat, G. N. Lack of eradication of Helicobacter pylori after omeprazole. Lancet 337, 1093 (1991).

    Article  CAS  PubMed  Google Scholar 

  138. Labenz, J., Gyenes, E., Ruhl, G. H. & Borsch, G. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut 34, 1167–1170 (1993).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Labenz, J., Gyenes, E., Ruhl, G. H. & Borsch, G. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am. J. Gastroenterol. 88, 491–495 (1993).

    CAS  PubMed  Google Scholar 

  140. Bayerdorffer, E. et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand. J. Gastroenterol. Suppl. 196, 19–25 (1993).

    Article  CAS  PubMed  Google Scholar 

  141. Bazzoli . et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment. Pharmacol. Ther. 12, 439–445 (1998).

    Article  CAS  PubMed  Google Scholar 

  142. Lamouliatte, H. et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. Am. J. Gastroenterol. 93, 1531–1534 (1998).

    Article  CAS  PubMed  Google Scholar 

  143. Yousfi, M. M. et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 9, 209–212 (1995).

    Article  CAS  PubMed  Google Scholar 

  144. Yousfi, M. M., el-Zimaity, H. M., Gentam, R. M. & Graham, D. Y. One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 10, 617–621 (1996).

    Article  CAS  PubMed  Google Scholar 

  145. Lind, T. et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1, 138–144 (1996).

    Article  CAS  PubMed  Google Scholar 

  146. Malfertheiner, P. et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment. Pharmacol. Ther. 13, 703–712 (1999).

    Article  CAS  PubMed  Google Scholar 

  147. Zanten, S. J. et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment. Pharmacol. Ther. 13, 289–295 (1999).

    Article  CAS  PubMed  Google Scholar 

  148. Megraud, F. et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob. Agents Chemother. 43, 2747–2752 (1999).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Becx, M. C., Janssen, A. J., Calsener, H. A. & de Koning, R. W. Metronidazole-resistant Helicobacter pylori. Lancet 335, 539–540 (1990).

    Article  CAS  PubMed  Google Scholar 

  150. Weil, J. et al. Helicobacter pylori and metronidazole resistance. Lancet 336, 1445 (1990).

    Article  CAS  PubMed  Google Scholar 

  151. Rautelin, H., Seppala, K., Renkonen, O. V., Vainio, U. & Kosunen, T. U. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob. Agents Chemother. 36, 163–166 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Xia, H. X., Buckley, M., Keane, C. T. & O'Morain, C. A. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J. Antimicrob. Chemother. 37, 473–481 (1996).

    Article  CAS  PubMed  Google Scholar 

  153. van Zwet, A. A. et al. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. Eur. J. Clin. Microbiol. Infect. Dis. 15, 861–864 (1996).

    Article  CAS  PubMed  Google Scholar 

  154. Graham, S. Y. et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102, 493–496 (1992).

    Article  CAS  PubMed  Google Scholar 

  155. Malfertheiner, P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand. J. Gastroenterol. Suppl. 196, 34–37 (1993).

    Article  CAS  PubMed  Google Scholar 

  156. Forne, M. et al. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. Am. J. Gastroenterol. 93, 35–38 (1998).

    Article  CAS  PubMed  Google Scholar 

  157. Bigard, M. A., Delchier, J. C., Riachi, G., Thibault, P. & Barthelemy, P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment. Pharmacol. Ther. 12, 383–388 (1998).

    Article  CAS  PubMed  Google Scholar 

  158. Zullo, A. et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 14, 715–718 (2000).

    Article  CAS  PubMed  Google Scholar 

  159. Wu, D. C. et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin. Gastroenterol. Hepatol. 8, 36–41 (2010).

    Article  CAS  PubMed  Google Scholar 

  160. Hsu, P. I., Wu, D. C., Wu, J. Y. & Graham, D. Y. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 16, 139–145 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Zullo, A. et al. Concomitant, sequential, and hybrid therapy for, H. pylori eradication: a pilot study. Clin. Res. Hepatol. Gastroenterol. 37, 647–650 (2013).

    Article  CAS  PubMed  Google Scholar 

  162. Molina-Infante, J. et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 145, 121–128 (2013).

    Article  CAS  PubMed  Google Scholar 

  163. Szajewska, H., Horvath, A. & Piwowarczyk, A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment. Pharmacol. Ther. 32, 1069–1079 (2010).

    Article  CAS  PubMed  Google Scholar 

  164. Pallen, M. J. & Clayton, C. L. Vaccination against Helicobacter pylori urease. Lancet 336, 186–187 (1990).

    CAS  PubMed  Google Scholar 

  165. Chen, M., Lee, A. & Hazell, S. Immunisation against gastric helicobacter infection in a mouse/Helicobacter felis model. Lancet 339, 1120–1121 (1992).

    Article  CAS  PubMed  Google Scholar 

  166. Michetti, P. et al. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 107, 1002–1011 (1994).

    Article  CAS  PubMed  Google Scholar 

  167. Ferrero, R. L. et al. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc. Natl Acad. Sci. USA 92, 6499–6503 (1995).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Del Giudice, G., Malfertheiner, P. & Rappuoli, R. Development of vaccines against Helicobacter pylori. Expert Rev. Vaccines 8, 1037–1049 (2009).

    Article  CAS  PubMed  Google Scholar 

  169. Aebischer, T. et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 57, 1065–1072 (2008).

    Article  CAS  PubMed  Google Scholar 

  170. Malfertheiner, P. et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 135, 787–795 (2008).

    Article  CAS  PubMed  Google Scholar 

  171. Malfertheiner, P. et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 377, 905–913 (2011).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Leipziger Strasse 44, Magdeburg, D-39120, Germany

    Peter Malfertheiner, Alexander Link & Michael Selgrad

Authors
  1. Peter Malfertheiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Selgrad
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

P.M. and M.S. contributed to researching data, discussion of content, writing and reviewing/editing the manuscript before submission. A.L. contributed to researching data and writing the article.

Corresponding author

Correspondence to Peter Malfertheiner.

Ethics declarations

Competing interests

P.M. receives honoraria for speaking from Aptalis, AstraZeneca and Nycomed. The other authors declare no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Malfertheiner, P., Link, A. & Selgrad, M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol 11, 628–638 (2014). https://doi.org/10.1038/nrgastro.2014.99

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.99

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing